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On June 01, 2020, the outbreak of COVID-19 caused by 
SARS-CoV-2 has escalated to 6.3 million cases worldwide, 
including 374,000 deaths. Severe lung disease with acute 
respiratory distress syndrome represents one of the 
most common complications. Additionally, myocardial 
injury is present in more than a quarter of critical cases, 
manifesting either acutely on presentation or more 
insidiously as illness severity intensifies (1, 2, 3, 4).
Clinical signs of cardiovascular disease include 
chest pain, fulminant myocarditis, arrhythmias, acute 
coronary artery disease, and heart failure. More recently, 
microvascular disease syndromes have been reported, 
including cutaneous reticular livedo (5, 6). Some cases of 
Kawasaki disease, in which blood vessels throughout the 
body become inflamed and can form aneurysms, have 
been also reported. However, this figure is lower than 
would be normally expected at this time of year when 
Kawasaki disease generally peaks (https://www.rcpch.
ac.uk/news-events/news/college-responds-recent-reports-
covid-19-children).
Media articles on Kawasaki disease were confusing 
and have caused public concern. This calls for cautious 
interpretation and communication of research outputs, a 
difficult task in a global emergency requiring immediate 
medical solutions. Two COVID-19 priority studies in the 
UK (DIAMONDS (Central Portfolio Management System 
45537) and ISARIC (UK Clinical Research Network 14152)) 
are collaborating in a study exploring prevalence of the 
disease and underpinning mechanisms.
Researchers around the world are racing to learn how 
the virus behaves and which health factors put people 
most at risk. The crucial question they are trying to work 
out is whether there may be some specific mechanism in 
cells of the lung and heart that could mean some people 
suffer respiratory complications and heart attacks more 
than others. While the increased frailty of cardiovascular 
patients may account for the susceptibility to infection 
and organ damage, the reason why COVID-19 causes 
cardiovascular complications is less obvious.
SARS-CoV-2 has adopted a successful tactic to infect, 
damage, and spread. The virus binds with its spike protein 
to the surface receptor angiotensin converting enzyme 2 
(ACE2) to unlock human cells and begin infection. We 
know relatively little of the stoichiometry of the virus – 
human cell receptor interaction. The minimum number 
necessary for infection varies between different viruses 
and it is not clear what is minimum infectious dose for 
COVID-19. Likewise, it remains to be established whether 
repeated exposures or a single contact with massive doses 
of the virus, like in the case of clinical staff caring patients 
who are not known to be infected, can increase the risk of 
developing severe forms of the disease.
The second element to consider is the binding affinity 
of the viral spike protein for the human cell receptor. 
The binding of SARS-CoV-2 to ACE2 is stronger than 
previous coronaviruses, due to difference in key amino 
acid residues allowing for enhanced interactions between 
the virus and human cells. This may explain the larger 
global impact of COVID-19 as compared with SARS. 
Interfering with binding of SARS-CoV-2 to ACE2 could be 
a means to attenuate infection, while waiting for vaccine 
availability. In this respect, the use of the extracellular 
domain of ACE2 could represent a solution to sponge 
the virus before it can reach cell membrane bound ACE2 
receptors. It is not clear whether having high circulating 
levels of ACE2 are protective, neutral, or negative in terms 
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of risk of infection and disease severity and if there is a 
relationship, either positive or negative, between the levels 
of soluble and membrane bound ACE2. A recent study 
has shown a modest increase of circulating ACE2 in men 
with cardiovascular disease, with no significant difference 
between those on ACE inhibitors vs other treatments (7). 
The authors have extrapolated this into an increase risk 
for COVID-19 in men, but no data have been reported in 
COVID-19 patients and the observed difference was small 
in magnitude and of uncertain relevance for explaining a 
higher prevalence of COVID-19 between sexes.
The third and most debated stoichiometric variable is 
represented by the number of receptors expressed on the 
surface of cells. As yet, the possibility that severity and type 
of complications are influenced by ACE2 expression levels 
in different organs is contradictory and unsupported by 
causative evidence. We just do not know if having high or 
low ACE2 expression on cell membrane is good or bad for 
people with COVID-19 and which change in expression, 
if any, could make a difference.
A negative correlation between ACE2 expression 
and COVID-19 related morbidity and mortality has been 
reported in population studies, with low-risk categories 
(children and women) having high ACE2 levels and high-
risk categories (elderly people and men) having low ACE2 
levels. People over the age of 60 years are at a significantly 
greater risk of COVID-19. This includes an increased 
risk of severe illness, hospitalisation, intensive care unit 
admission and death (8). Therefore, when considering 
severity of COVID-19, the low ACE2 levels observed in 
elderly people and those with cardiovascular disease seem 
to facilitate rather than protect from the disease (9). Other 
aspects should be considered; in particular, in older people, 
the activation of the immune system may be delayed. 
This means that the virus can continue replicating and 
spreading in the body causing more extensive damage.
Several studies have evaluated the expression of ACE2 
at organ and even at single cell level. A pre-print article, 
posted on MedRxiv, reported that gonads express high 
levels of ACE2 and could therefore act as a reservoir for 
SARS-CoV-2. The authors proposed this could be a reason 
for the longer duration of COVID19 in men (https://
www.medrxiv.org/content/10.1101/2020.04.16.200605
66v1). Studies investigating the expression of ACE2 at a 
single cell level in the heart have shown that perivascular 
cells, alias pericytes, that wrap coronary capillaries and 
arterioles, abundantly express ACE2 and hence could be 
a special target for SARS-CoV-2 infection in the heart (10, 
11). It was suggested that patients taking ACE inhibitors 
should be strictly monitored because ACE inhibition can 
increase ACE2 expression, thereby increasing the risk of 
infection. International cardiovascular societies do not 
consider this evidence is strong enough to stop ACE 
inhibitors in COVID-19 patients.
Noteworthy, the possibility that SARS-CoV-2 infects 
organs beside the airways is yet to be demonstrated. 
Although viral genetic material (viral-RNA) can be found 
in different organs including the myocardium, there is no 
substantial evidence that the virus replicates outside the 
lung (MedRxiv DOI: 10.1101/2020.03.05.20030502). Viral 
RNA in the heart may reflect killed or inactivated virus 
that is no longer infectious. Cardiovascular complications 
should be therefore reconducted to indirect effects, as also 
suggested by the observation that they often occur after 
seroconversion, that is, the transition from infection to 
the detectable presence of antibodies in the blood.
One indirect mechanism of cardiovascular damage 
in COVID-19 is represented by the induction of an 
exaggerated inflammatory reaction, the cytokine storm. 
Cytokine storms are a common complication not only 
of COVID-19 but of other respiratory diseases caused 
by coronaviruses such as SARS and MERS. They can 
sometimes occur in patients suffering from non-infectious 
diseases such as multiple sclerosis and pancreatitis. The 
Recovery Trial has shown that steroid treatment with low-
dose dexamethasone may improve the outcome of critical 
patients (Clinical Trials.gov: NCT04381936)
Secondly, it is well established that there is often an 
association of transient production of autoantibodies 
with common viral infections. Autoantibodies can 
be induced because of cross-reactivity between viral 
proteins and autoantigens, molecular mimicry, and the 
induction of apoptosis of virus-infected cells. Another 
theory suggests that autoantibodies are anti-idiotypic 
antibodies to antiviral antibodies. Some of the commonly 
tested autoantibodies in viral infections include 
antinuclear antibodies (ANAs), antibodies directed against 
nucleoproteins, that is, extractable nuclear antibodies 
(ENA) and phospholipids, and antineutrophil cytoplasmic 
antibodies (ANCAs). In addition, cells of the immune 
system may produce antibodies specific to certain tissues 
or organs. Previous studies showed that autoantibodies 
against human epithelial cells and endothelial cells after 
SARS-CoV infection were responsible for SARS-induced 
immunopathology (12). A case report study published 
in the New England Journal of Medicine showed some 
severe cases of COVID-19 presented clinically significant 
coagulopathy, antiphospholipid antibodies, and multiple 
infarcts (13). The antiphospholipid syndrome is an 
autoimmune condition, which in the most catastrophic 
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variant results in multiple thromboses, organ failure 
and death. More research is needed on autoimmunity in 
COVID-19.
Finally, fragments of SARS-CoV-2, including capsid 
proteins, may continue to circulate in the bloodstream 
after virus inactivation and seroconversion. Fusion of 
spike protein to ACE2 would be sufficient to interfere 
with receptor-mediated signalling, independently of the 
virus. In this respect, the ACE2 hypothesis could provide 
an intriguing explanation not only for the path used by 
the virus to infect certain cells in the body but also for 
the modalities by which the virus and/or viral proteins 
interfere with cardiovascular physiology (Fig. 1). ACE2 
is responsible for the formation of vasodilator Ang 1–7, 
which normally opposes the action of ACE-generated 
Ang II. We speculate that, after engagement with the ACE2 
receptor, the viral protein‒ACE2 complex is internalized, 
leading to ACE2 degradation. As a consequence, Ang 
II will prevail over anti-inflammatory Ang 1-7; this 
imbalance resulting in activation of Ang type 1 receptor 
(AT1R) on vascular cells, causing vasoconstriction, 
vascular permeability, oxidative stress, and inflammation. 
Figure 1
ACE2 downregulation by SARS-CoV-2 induces pericyte damage and microvascular dysfunction. (A) SARS-CoV-2 uses the ACE2 receptor for entry and the 
serine protease TMPRSS2 for S protein priming. (B) ACE2-mediated cardiovascular protection is lost following endocytosis of the receptor along with 
SARS-CoV-2 viral particles. (C) Unopposed ACE activity leads to Ang II generation with increased activity of angiotensin 1 receptors (AT1R) at the cost of 
ACE2/Ang 1–7 driven pathways. (D) This leads to increased reactive oxygen species (ROS), vasoconstriction, vascular permeability, oxidative stress, and 
inflammation.Moreover,ACE2downregulationresultsinincreasedlevelofDes-Arg9-bradykinin(normallydegradedbyACE2)whichthroughthekinin
receptorB1(B1R)causesvascularleakageandinflammation.(E)ADAM17mediatedproteolyticcleavageofACE2isupregulatedbyendocytosed
SARS-CoV-2 spike proteins. Activation of the AT1R by elevated Ang II levels also further increases ADAM17 activity. Soluble ACE2 can act as a blocking 
receptor for SARS-CoV-2. (F) After replication and cellular damage, the virus spreads to other cells causing incremental injury and vascular dysfunction. 
Alternatively, if the virus does not reach the heart, viral particles and proteins could do so, activating the described signalling pathway.
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The AT1R signals through the protein kinase (MAPK) 
signalling pathway and phosphorylation of ADAM-
17, which increases ACE2 shedding, enhancing the 
downregulation of ACE2 in an incremental feedback 
cycle.
Moreover, ACE2 is responsible for the degradation 
of pro-inflammatory kinin des-Arg9-bradykinin (DABK). 
Disruption of ACE2 could exert additional detrimental 
effects in COVID-19 through undegraded DABK binding to 
the bradykinin B1 receptor (BKB1R). An excess DABK may 
contribute in causing microvascular leakage, leukocyte 
extravasation, and pulmonary oedema in COVID-19 
(https://www.preprints.org/manuscript/202004.0023/v1).
In conclusion, several lessons can be learnt from the 
COVID-19 pandemic. On the one side, researchers should 
not be too precipitous in reaching causative conclusions 
from correlative associations. On the other side, in-depth 
knowledge of mechanisms used by viruses to thrive and 
spread can lead to new treatments of viral disease, but 
also to novel therapeutic approaches of cardiovascular 
pathologies. For instance, engineered viral proteins could 
be used to produce specific or wide-spectrum vaccines 
as well as to induce or inhibit key signalling pathways 
implicated in cardiovascular disease.
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